Development of an innovative, class-leading, low-molecular, double-oriented therapeutic agent having immunomodulating and cytotoxic effects as a drug candidate for the treatment of leukaemia and solid tumours
Funding Agreement No.: POIR.01.01.01-00-0472/19-00 under Measure 1.1: “R&D projects of companies”
Date of the contract conclusion: 07/11/2019
The aim of the project is to develop a first-in-class, innovative dual inhibitor which can tolerate immunosuppression and cytotoxic effects on cancer cells, as well as its clinical evaluation as a drug candidate for treatment of selected solid tumours and leukaemia.
As part of the project, the Applicant expects the selection and validation of a molecular biomarker to support the assessment of therapy efficacy.
Total value of the CITY project: PLN 45,757,190.00
Total value of funding: PLN 27,936,255.00